If you or your patient don undergo CT scan before, you go fit hear doctor or radiographer talk about “contrast dye.” Make we no waste time at all—Omnipaque (iohexol) na one of the most trusted non-ionic, water-soluble, iodine-based contrast media wey doctors use inside diagnostic imaging across hospitals worldwide.
Whether you be medical professional, radiography practitioner, or patient wey wan understand how this contrast agent works, this guide breakdown everything you need to know about Omnipaque from dosage across age groups to clinical safety, adverse reactions, and regulatory standards.
Omnipaque – CT Contrast (Buy In Nigeria)
Call or WhatsApp Below To Buy. Click Below To Get Started: Call 0707 1010 100
Omnipaque is a tri-iodinated, non-ionic contrast medium containing iohexol as its active ingredient. It is engineered to attenuate X-ray beams as they pass through the body.
Because iodine has a high atomic number ($Z=53$), it absorbs X-ray photons effectively. When introduced into organs, body cavities, or blood vessels, Omnipaque temporarily increases the radiological density of target tissues relative to surrounding structures, allowing high-resolution visualization during Computed Tomography (CT) and radiographic examinations.
Key Clinical Takeaway: Non-ionic contrast agents like Omnipaque feature lower osmolality compared to older ionic agents. This lower osmolality significantly reduces systemic chemotoxicity, patient discomfort (such as severe heat flush), and adverse allergic reactions.
What is Omnipaque Used For?
Omnipaque is indicated for diagnostic radiologic procedures across multiple organ systems:
Note: Dosing depends directly on iodine concentration (e.g., Omnipaque 140, 240, 300, 350 mg I/mL), body weight, renal function, and specific imaging protocol.
Dosing Overview Table
Patient Group
Recommended Dosage Range
Primary Route
Max Administered Limits
Adults
60 mL – 100 mL (CT Body)
80 mL (CT Head)
IV, Oral, Intra-arterial
Max 250 mL total dose
Children (Pediatrics)
1.0 mL/kg to 2.0 mL/kg
IV, Oral, Rectal
Max 3.0–5.0 mL/kg (Not to exceed 250 mL)
Infants (< 1 Year)
0.5 mL/kg to 1.5 mL/kg
IV, Oral (Diluted 9–21 mg I/mL)
Dose capped by iodine load limit
Adult Dosage & Prescription
Prescription For Adult:For routine CT body scan, standard adult volume ranges between 60 mL and 100 mL of Omnipaque 350. For head imaging, 80 mL of Omnipaque 350 is routinely administered IV.
Adult Schedule: Bolus administration right before or during scan acquisition using an automated power injector.
Child Dosage & Prescription
Prescription For Child (1–12 Years): Administered strictly on a body-weight basis ($1.0\text{ mL/kg}$ to $2.0\text{ mL/kg}$).
Schedule & Dose Per Day: Single diagnostic procedure administration; cumulative pediatric dose must not exceed $5\text{ mL/kg}$ up to a maximum total of $250\text{ mL}$.
Infant Dosage & Prescription
Prescription For Infant (< 12 Months): Micro-dosing calculated carefully ($0.5\text{ mL/kg}$ to $1.5\text{ mL/kg}$).
Infant Schedule: Given under strict pediatric monitoring. Hydration status must be corrected prior to administration to avoid Contrast-Induced Nephropathy (CIN).
Active & Inactive Ingredients
Active Ingredients:Iohexol ($\text{C}_{19}\text{H}_{26}\text{I}_3\text{N}_3\text{O}_9$).
Inactive Ingredients (Excipients): Tromethamine (Tris buffer), edetate calcium disodium (chelating agent), hydrochloric acid and/or sodium hydroxide (for pH adjustment between 6.8 and 7.7), and Water for Injection.
Adverse Effects, Contraindications & Warnings
Common Adverse Reactions
Mild sensation of warm flushing across body during IV injection.
Transient metallic taste in the mouth.
Mild nausea or vomiting.
Transient headache or dizziness.
Diarrhea (frequent with oral administration, up to 42%).
Serious Reactions & Allergens
Allergic Reactions:Urticaria (hives), angioedema, bronchospasm, or anaphylaxis.
Contrast-Induced Acute Kidney Injury (CI-AKI):Transient decrease in renal function.
Severe Cutaneous Reactions:Stevens-Johnson syndrome (SJS) or Toxic Epidermal Necrolysis (TEN).
Contraindications & Precautions
Known Hypersensitivity: Previous severe systemic response to iohexol or iodinated contrast.
Thyroid Dysfunction:Risk of precipitating thyrotoxicosis or thyroid storm.
Pregnancy & Lactation: Use only if clinically essential. Breastfeeding may be paused for 10–24 hours post-exposure according to local guidelines.
Injections, Syringes, & IV Delivery Systems
How contrast media is handled directly affects patient safety and image quality.
Prefilled Syringes: Factory-sealed, unit-dose prefilled syringes reduce contamination risks, speed up scan preparation, and eliminate dosage measurement errors in high-volume radiology suites.
Safety Syringes: Needleless safety valves and luer-lock system connectors minimize needle-stick injury risks for healthcare staff during power-injector setup.
Intravenous (IV) Therapy & Power Injectors: Intravenous injection requires high-gauge peripheral lines (18G–20G) to handle high injection flow rates (up to 4–6 mL/s) necessary for multiphasic CT scans (e.g., arterial vs. venous phase).
Subcutaneous and Intramuscular Delivery: Omnipaque is NOT administered via subcutaneous or intramuscular routes due to risk of tissue necrosis and severe local inflammation.
Surgical Procedures & Product Safety Protocols
When contrast agents are used alongside surgical intervention (e.g., hybrid operating rooms, surgical angiography):
Infection Prevention: Aseptic technique is mandatory. Contrast media contains no antimicrobial preservatives; opened containers must be used immediately or discarded.
Custom Procedure Trays (CPTs): Radiologic CPTs bundle sterile drape sheets, power injector tubing, luer connections, and prefilled contrast vials to maintain sterile fields.
Ergonomics & Usability: Power injector interfaces feature single-hand loading to increase operational efficiency during high-pressure vascular procedures.
Zero-Harm Initiatives: Pre-procedure safety checklists ensure baseline serum creatinine/eGFR checks, identification of iodine allergies, and confirmation of active patient hydration status.
Technical & Regulatory Data Overview
====================================================================
OMNIPAQUE (IOHEXOL) CLINICAL & REGULATORY MATRIX
====================================================================
[1] FORMULATION & DELIVERY METHOD
- Non-ionic, water-soluble tri-iodinated monomer.
- Solutions: 140, 180, 240, 300, 350 mg Iodine/mL.
- Routes: Intravenous, Intra-arterial, Oral, Rectal, Intrathecal.
[2] MECHANISM OF ACTION
- Attenuates X-rays proportional to iodine concentration.
- Increases radiodensity of blood vessels & soft tissues.
[3] PHARMACOKINETICS & ELIMINATION
- Minimal plasma protein binding (< 2%).
- Renal Excretion: > 90% excreted unchanged in urine within 24h.
- Elimination Half-life: ~ 2 hours in patients with normal renal function.
[4] REGULATORY STATUS & GMP
- FDA Approved (Original Approval: 1985).
- Produced under strict Good Manufacturing Practices (GMP).
- Post-market pharmacovigilance monitors global adverse event reporting.
[5] STORAGE & SHELF LIFE
- Store at 20°C to 25°C (68°F to 77°F); excursions permitted.
- Protect from light and secondary X-rays. Do not freeze.
====================================================================
Medical Detail for Health Professionals
Drug Discovery, R&D, and Bioequivalence
Omnipaque (iohexol) was developed as a second-generation non-ionic monomer to solve the osmotic toxicity associated with first-generation ionic agents (like diatrizoate). By eliminating the dissociation into ions in solution, iohexol lowers osmolality while preserving high iodine content per molecule.
Generics vs. Brand-Name Contrast Media
While Omnipaque is the primary reference brand product developed by GE Healthcare, bioequivalent generic iohexol formulations operate under identical international pharmacopeial standards. Formulary inclusion depends on hospital purchasing models, bioequivalence data, and container compatibility with automated delivery systems.
Clinical Pharmacovigilance & Overdosage Protocols
In cases of accidental massive overdosage, patient management involves:
Immediate support of respiratory and hemodynamic functions.
Intensive IV hydration to promote renal excretion.
Hemodialysis if acute renal failure develops or severe overdose occurs in compromised patients.
Similar Contrast Agents (Alternatives)
Brand Name
Generic Name
Type
Key Features
Omnipaque
Iohexol
Non-ionic monomer
High versatility (IV, Oral, Intrathecal)
Visipaque
Iodixanol
Non-ionic dimer
Iso-osmolar to blood ($290\text{ mOsm/kg H}_2\text{O}$)
Ultravist
Iopromide
Non-ionic monomer
Low viscosity, rapid vascular visualization
Isovue
Iopamidol
Non-ionic monomer
Widely used for cardiac and IV CT protocols
Final Words
Omnipaque (iohexol) remains a cornerstone in modern diagnostic radiology. Its balance of high radiodensity, low osmolality, and established clinical safety across neonates, children, and adults makes it invaluable for high-precision CT scanning.
Disclaimer: This article is strictly for educational and informational purposes. Contrast media must be administered under the direct supervision of certified radiologic technologists and medical specialists.
Omnipaque – CT Contrast (Buy In Nigeria)
Product photos are not displayed because designs update on daily basis, but the item is in stock and we are ready to sell - contact us now to see the latest version of this product.
Call or WhatsApp Below To Buy. Click Below To Get Started: Call 0707 1010 100
